Amylyx Pharmaceuticals Future Growth
Future criteria checks 0/6
Amylyx Pharmaceuticals's revenue and earnings are forecast to decline at 80.8% and 18.7% per annum respectively while EPS is expected to decline by 17.5% per annum.
Key information
-18.7%
Earnings growth rate
-17.5%
EPS growth rate
| Pharmaceuticals earnings growth | 21.0% |
| Revenue growth rate | -80.8% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Apr 2024 |
Recent future growth updates
Recent updates
Analysts Just Shaved Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Forecasts Dramatically
Mar 12
An ALS Drug Fails Again
Mar 09Amylyx Pharmaceuticals: Q4 Earnings Insight And PHOENIX Trial Implications
Feb 23Amylyx Pharmaceuticals, Inc.'s (NASDAQ:AMLX) 27% Price Boost Is Out Of Tune With Revenues
Feb 23Take Care Before Jumping Onto Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Even Though It's 34% Cheaper
Nov 10Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Sep 24This Just In: Analysts Are Boosting Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Outlook for This Year
May 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Strong Position To Grow Its Business
Apr 20Earnings Update: Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Just Reported And Analysts Are Boosting Their Estimates
Mar 16Amylyx Pharmaceuticals (NASDAQ:AMLX) Is In A Good Position To Deliver On Growth Plans
Dec 19Amylyx Pharmaceuticals prices $214.2M upsized stock offering at $32.00/share
Oct 07Amylyx ALS Drug Approval: Unexpected, Welcome, And Conditional - May Put Share Price In Stasis
Sep 30Amylyx Pharma stock surges 81% after ALS drug gets FDA advisers backing
Sep 08Amylyx plunges 28% after FDA briefing documents on ALS drug
Sep 02We're Not Very Worried About Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
Aug 29Amylyx Pharmaceuticals GAAP EPS of -$0.93 misses by $0.01
Aug 11Amylyx Pharmaceuticals says ALS treatment Albrioza now available in Canada
Jul 29Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates
Jul 18Amylyx: Thoughts Ahead Of September 29 PDUFA In Amyotrophic Lateral Sclerosis
Jul 04Amylyx Pharmaceuticals: Share Price Bump On Canada Approval For ALS Drug May Not Last
Jun 17We're Keeping An Eye On Amylyx Pharmaceuticals' (NASDAQ:AMLX) Cash Burn Rate
May 07Amylyx: Crucial Advisory Committee Meet Tomorrow, Approval Chancy
Mar 29Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 0 | -80 | 74 | N/A | 5 |
| 12/31/2025 | 0 | -85 | 44 | N/A | 6 |
| 12/31/2024 | 102 | -105 | 0 | N/A | 6 |
| 12/31/2023 | 381 | 49 | 11 | 12 | N/A |
| 9/30/2023 | 294 | 2 | -53 | -51 | N/A |
| 6/30/2023 | 192 | -73 | -91 | -89 | N/A |
| 3/31/2023 | 94 | -149 | -147 | -144 | N/A |
| 12/31/2022 | 22 | -198 | -182 | -180 | N/A |
| 9/30/2022 | 0 | -184 | -161 | -158 | N/A |
| 6/30/2022 | 0 | -153 | -138 | -136 | N/A |
| 3/31/2022 | 0 | -121 | -103 | -103 | N/A |
| 12/31/2021 | 0 | -88 | -75 | -75 | N/A |
| 9/30/2021 | 1 | -68 | -56 | -55 | N/A |
| 12/31/2020 | 1 | -42 | -37 | -37 | N/A |
| 12/31/2019 | 1 | -14 | -11 | -11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: AMLX's earnings are forecast to decline over the next 3 years (-18.7% per year).
Earnings vs Market: AMLX's earnings are forecast to decline over the next 3 years (-18.7% per year).
High Growth Earnings: AMLX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: AMLX's revenue is expected to decline over the next 3 years (-80.8% per year).
High Growth Revenue: AMLX's revenue is forecast to decline over the next 3 years (-80.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if AMLX's Return on Equity is forecast to be high in 3 years time